Core Viewpoint - Maravai LifeSciences Holdings, Inc. is facing a class action lawsuit due to allegations of false and misleading statements regarding its financial reporting and revenue recognition practices during the specified class period [3][4]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Maravai securities between August 7, 2024, and February 24, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations Against Maravai - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting, particularly concerning revenue recognition [3]. - It is alleged that Maravai improperly recognized approximately $3.9 million in revenue during fiscal year 2024 due to an error in recording revenue [4]. - The company is also accused of overstating its goodwill related to its acquisition of Alphazyme LLC [3][4]. Group 3: Impact on Stock Price - Following the announcement of the postponement of its fiscal 2024 earnings release and the need for additional time to complete its financial close, Maravai's stock price fell by nearly 22% [4].

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 03, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Elastic N.V. ("Elastic" or the "Company") (NYSE: ESTC) investors of a class action representing investors that bought securities between May 31, 2024 and August 29, 2024, inclusive (the "Class Period"). Elastic investors have until April 14, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, b ...

Core Viewpoint - A class action lawsuit has been initiated against Monolithic Power Systems, alleging misleading statements and undisclosed quality control issues that have negatively impacted its relationship with Nvidia and its financial performance [3][4][5]. Group 1: Company Overview - Monolithic Power Systems specializes in power management components for electronic systems, with Nvidia Corporation as its largest customer [2]. Group 2: Legal Action - Investors who purchased Monolithic Power Systems securities between February 8, 2024, and November 8, 2024, are eligible to join the class action lawsuit, with a deadline to file a lead plaintiff motion by April 7, 2025 [1]. Group 3: Allegations and Impact - The lawsuit claims that Monolithic Power Systems failed to disclose significant performance and quality control issues with its voltage regulator modules and power management integrated circuits, which adversely affected Nvidia products [3]. - Following the disclosure of a revenue decline in the Enterprise Data segment, Monolithic Power Systems' stock price fell over 17% after missing analysts' estimates [4]. - A subsequent report indicated that Nvidia canceled half of its orders with Monolithic Power Systems and planned to exclude its components from future products due to performance issues, leading to an additional stock price drop of nearly 15% [5].

Core Viewpoint - Merck & Co., Inc. is facing a class action lawsuit from investors due to a significant drop in stock price following the company's announcement that it would not meet its projected $11 billion revenue from Gardasil sales by 2030 [1][4]. Group 1: Class Action Details - The class action represents investors who purchased Merck securities between February 3, 2022, and February 3, 2025, with a deadline to file a lead plaintiff motion by April 14, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Financial Projections and Impact - The complaint highlights that Merck had projected $11 billion in revenue from Gardasil sales by 2030, supported by optimistic forecasts regarding demand in China [3]. - On February 4, 2025, Merck announced it would halt Gardasil shipments to China, leading to a stock price drop from $99.79 to $90.74 per share, a decline of over 9% in one day [4].

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 25, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Newmont Corporation ("Newmont" or the "Company") (NYSE: NEM) investors of a class action representing investors that bought securities between February 22, 2024 and October 23, 2024, inclusive (the "Class Period"). Newmont investors have until April 1, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. ...

Core Viewpoint - A class action lawsuit has been initiated against Monolithic Power Systems, alleging misleading statements and undisclosed performance issues with its products, particularly affecting its relationship with Nvidia [3]. Group 1: Class Action Lawsuit - The class action represents investors who purchased Monolithic Power Systems securities between February 8, 2024, and November 8, 2024 [1]. - Investors have until April 7, 2025, to file a lead plaintiff motion [1]. - The lawsuit claims that the company failed to disclose significant performance and quality control issues with its voltage regulator modules and power management integrated circuits [3]. Group 2: Financial Performance - On October 30, 2024, Monolithic Power Systems reported a revenue decline in its Enterprise Data segment to $184 million, missing analysts' estimates of $211 million by nearly 13% [4]. - Following this financial report, the company's stock price dropped more than 17% [4]. Group 3: Relationship with Nvidia - A report from Edgewater Research on November 11, 2024, indicated that Nvidia canceled half of its outstanding orders with Monolithic Power Systems due to performance issues [5]. - Nvidia's engineers reportedly lost confidence in Monolithic Power Systems' components, leading to a shift towards competitors [5]. - Following the news of order cancellations, Monolithic Power Systems' stock price fell nearly 15% [5].

Core Viewpoint - Integral Ad Science Holding Corp. (IAS) is facing a class action lawsuit due to alleged misrepresentations regarding its pricing strategy and competitive pressures during the specified class period from March 2, 2023, to February 27, 2024 [1][3]. Group 1: Legal Action - Investors who purchased IAS securities during the class period can file a lead plaintiff motion by March 31, 2025 [1]. - The Portnoy Law Firm is offering a complimentary case evaluation for investors to discuss their legal rights and options for recovering losses [2]. Group 2: Allegations Against IAS - The complaint alleges that IAS misrepresented key issues, including the emergence of significant competitive pricing pressures that forced the company to lower prices due to weaker demand and slower revenue growth [3]. - It is claimed that IAS's pricing strategy was no longer advantageous, impacting its ability to maintain or raise prices as previously expected [3]. - The complaint also states that pricing had become a critical factor in differentiating IAS from competitors, which was essential for securing major renewals and new contracts [3]. - Furthermore, it is alleged that the risks of increased competition leading to pricing pressures had already materialized, rendering IAS's public statements during this period materially false and misleading [3].

Core Viewpoint - A class action lawsuit has been initiated against Novo Nordisk A/S, alleging that the company made false or misleading statements regarding its CagriSema obesity treatment during the class period from November 2, 2022, to December 19, 2024, leading to significant investor losses [1][3]. Summary by Sections Class Action Details - Investors who purchased Novo Nordisk securities during the specified class period can file a lead plaintiff motion by March 25, 2025 [1]. - The Portnoy Law Firm is offering complimentary case evaluations to affected investors [2]. Allegations Against Novo Nordisk - The lawsuit claims that Novo Nordisk misrepresented the reliability of projected success for the Phase 3 CagriSema obesity study, "REDEFINE-1," and did not adequately discuss dosage tolerability [5]. - The company’s claims that CagriSema would achieve at least 25% weight loss in the REDEFINE-1 study were deemed unrealistic [5]. - The flexible protocol of the study limited its ability to provide meaningful weight loss data, suggesting potential issues with dosage tolerability or a rushed patient selection process [5]. Impact on Stock Price - Following the release of results from the REDEFINE-1 trial on December 20, 2024, Novo Nordisk's stock price experienced a nearly 18% drop, indicating a significant market reaction to the disclosed information [3].

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) investors of a class action representing investors that bought securities between February 3, 2022 and February 3, 2025, inclusive (the "Class Period"). Merck investors have until April 14, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portno ...